Lantheus (NASDAQ:LNTH) Stock Rating Upgraded by William Blair

Lantheus (NASDAQ:LNTH) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a report issued on Thursday, Marketbeat Ratings reports.

A number of other equities research analysts have also weighed in on LNTH. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday. Citizens Jmp lifted their price target on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday. Mizuho boosted their price objective on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial raised their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $78.83.

Lantheus Trading Down 0.3%

Lantheus stock traded down $0.25 during trading hours on Thursday, reaching $75.47. The stock had a trading volume of 1,150,332 shares, compared to its average volume of 841,698. The company has a fifty day simple moving average of $67.76 and a 200-day simple moving average of $59.90. Lantheus has a 52 week low of $47.25 and a 52 week high of $111.29. The stock has a market cap of $5.00 billion, a PE ratio of 31.82 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The company had revenue of $406.79 million during the quarter, compared to analyst estimates of $367.03 million. During the same period in the prior year, the business posted $1.59 earnings per share. Lantheus’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Analysts forecast that Lantheus will post 6.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently made changes to their positions in LNTH. Hantz Financial Services Inc. boosted its position in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Lantheus during the second quarter valued at $26,000. First Horizon Corp bought a new stake in Lantheus in the third quarter worth $26,000. Smartleaf Asset Management LLC grew its stake in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.